Company
PATH FERTILITY
SpermQT™ by Path Fertility helps predict pregnancy outcomes by measuring sperm function, not just sperm count, giving you clearer information for decisions like whether to continue with IUI (Intrauterine Insemination) or move to IVF (In vitro fertilization).¹·²·³
Also known as Inherent Biosciences, Inc.
- Status
- Operatingas of 2026-09-21
- Business model
- B2B2C
- Customers
- Future Parents and Providers
- Legal name
- Inherent Biosciences, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
SpermQT identifies subfertile men who go undiagnosed by the standard semen analysis. Early and accurate diagnosis can reduce ineffective fertility treatments, lower costs, and enhance patient well-being by ensuring that the right fertility treatments are provided from the start.
Funding snapshot
- Total raised
- $1.5MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $1.5M2022-08-19
Funding rounds
- Round, 2022
- $1.5M2022-08-19, SEC form D sold, 12 investors
Products
- Other
- SpermQT
Loading relationship preview